

Att. Docket No.: REG 710E

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Yuping Xia, et al.

Serial No.: to be assigned

Div. of USSN 09/773,877

Group: to be assigned

Filing Date: Concurrently herewith

Examiner: to be assigned

Title: METHODS OF TREATING INFLAMMATORY SKIN DISEASES

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents
US Patent & Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.


REQUEST FOR TRANSFER OF REFERENCE COPIES

[X] Applicants respectfully request that the cited references filed in the Information Disclosure Statement submitted in connection with parent application USSN 09/773,877, filed January 31, 2001, be transferred to the subject application for consideration by the Examiner

Fees

No fee deemed necessary. However, if any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-0650.

Respectfully submitted



Valeta Gregg
Reg. No. 35,127
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No.: : REG 710E

USSN : to be assigned
Div. of USSN: 09/773,877

Applicant : Yuping Xia, et al.

Date Filed : Concurrently herewith

For : METHODS OF TREATING
INFLAMMATORY SKIN DISEASES

Examiner : TO BE ASSIGNED

Group Art Unit : TO BE ASSIGNED

U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
_____	<u>6,011,003</u>	<u>1/4/00</u>	<u>Charnock-Jones, et al.</u>	_____	_____
_____	<u>5,712,380</u>	<u>1/27/98</u>	<u>Kendall, et al.</u>	_____	_____

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation</u>	
					<u>Yes</u>	<u>No</u>
_____	<u>WO98/13071</u>	<u>4/2/98</u>	<u>PCT</u>	_____	_____	_____
_____	<u>WO97/44453</u>	<u>11/27/97</u>	<u>PCT</u>	_____	_____	_____

OTHER DOCUMENTS

Examiner
Initials

- _____ DeVries, C., et al., 1992, Science, "The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," 255:989-91.
- _____ Sharifi, J., et al., 1998, The Quarterly Journ of Nucl Med, "Improving monoclonal antibody pharmacokinetics via chemical modification," 42:242-49.
- _____ Jensen-Pippo, K. E., et al., 1996, Pharm Research, "Enteral Bioavailability of Human Granulocyte Colony Stimulating Factor Conjugated with Poly(ethylene glycol)," 13:102-7.
- _____ Tanaka, K., et al., 1997, Jpn J Cancer Res, "Characterization of the Extracellular Domain in Vascular Endothelial Growth Factor Receptror-1 (Flt-1 Tyrosine Kinase)," 88:867-76.
- _____ Tiilikainen, A., et al., 1980, Brit J of Dermatology, "Psoriasis and HLA-Cw6," 102:179-184.
- _____ Nickoloff B.J., 1999, Arch Dermatol, "The Immunologic and Genetic Basis of Psoriasis," 135:1104-10.
- _____ Altman, E., et al., 1999, Sem in Cutaneous Med and Surg, "Diagnosis: Psoriasis or Not? What are the Clues?" 18:25-35.

____ Detmar, M., et al., 1994, Journal of Exp Med, "Overexpression of Vascular Permeability Factor/vascular Endothelial Growth Factor and its Receptors in Psoriasis," 180:1141-6.

____ Detmar, M., et al., 1998, Journal of Invest Dermatol, "Increased Microvascular Density and Enhanced Leukocyte Rolling and Adhesion in the Skin of VEGF Transgenic Mice," 111(1):1-6.

____ Brown, L.F., et al., 1995, Journal of Invest Dermatol, "Increased Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Bullous Pemphigoid, Dermatitis Herpetiformis, and Erythema Multiforme," 104(5):744-9.

____ Suri, C., et al., 1998, Science, "Increased Vascularization in Mice Overexpressing Angiopoietin-1," 282:468-71.

____ DeLisser, H.M., et al., 1994, Immunol Today, "Molecular and functional aspects of PECAM-1/CD31," 15(10):490-5.

____ Wrone-Smith, T., and Nickoloff, B.J., 1996, J Clin Invest, "Dermal Injection of Immunocytes Induces Psoriasis," 98(8):1878-87.

____ Nickoloff, B.J., and Wrone-Smith, T., 1999, Am J of Pathol, "Injection of Pre-Psoriatic Skin with CD4+ T Cells Induces Psoriasis," 155(1):145-58.

____ Hunt, T.K., 1980, World J Surg., "Disorders of Wound Healing," 4:271-77.

_____ Dvorak, H.F., et al., 1995, Am J Pathol, "Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermeability, and Angiogenesis," 146(5):1029-39.

_____ Brown, L.F., et al., 1992, J Exp Med, "Expression of Vascular Permeability (Vascular Endothelial Growth Factor) by Epidermal Keratinocytes during Wound Healing," 176(5):1375-9.


EXAMINER
CONSIDERED

DATE

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:


Valeta Gregg
Reg. No. 35,127
Attorney for Applicants
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400